Interventional Radiology in Oncology

  • Michael K. Glynos
  • Katerina S. Malagari


Interventional radiology has long been contributing to the treatment of oncology patients by means of diagnostic procedures such as fine-needle aspiration or core biopsy under imaging guidance. IR techniques are worldwide used for palliative treatment: venous, biliary, esophageal, duodenal, enteric, ureteric, or airway obstructions due to malignant compression or infiltration are now being treated almost exclusively by percutaneous or transoral stent insertion. Percutaneous image-guided drainage, embolization, and stenting play a prominent role in management of complications of the initial disease or initial treatment. Vertebroplasty and cementoplasty are the current practice in management of certain bone metastases. Moreover, invention and development of medical devices led to a breakthrough of interventional radiology to potentially curative procedures. Transarterial chemoembolization and thermal tumor ablation are listed among the curative options for certain cancer patients; hence, they occupy the major part of this chapter.


  1. 1.
    Uberoi R, Morgan R (2006) CIRSE quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Interv Radiol 29:319–322CrossRefGoogle Scholar
  2. 2.
    Rosenthal DI, Hornicek FJ, Wolfe MW et al (1998) Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am 80(6):815–821CrossRefGoogle Scholar
  3. 3.
    Brace CL (2009) Radiofrequency and microwave ablation of the liver, lung, kidney and bone: what are the differences. Curr Probl Diagn Radiol 38:135–143CrossRefGoogle Scholar
  4. 4.
    Simon CJ, Dupuy DE, Mayo-Smith WN (2005) Microwave ablation: principles and applications. Radiographics 25:S69–S83CrossRefGoogle Scholar
  5. 5.
    Livraghi T, Meloni F, Solbiati L et al (2012) Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol 35:868–874CrossRefGoogle Scholar
  6. 6.
    Kojima Y, Suzuki S, Sakaguchi T et al (2000) Portal vein thrombosis caused by microwave coagulation therapy for hepatocellular carcinoma: report of a case. Surg Today 30:844–848CrossRefGoogle Scholar
  7. 7.
    Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113:2671–2680CrossRefGoogle Scholar
  8. 8.
    Yang Y, Wang C, Lu Y et al (2012) Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 19(6):674–684. Accessed 24 May 2011CrossRefGoogle Scholar
  9. 9.
    Smith MT, Ray CE (2006) The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy. Semin Interv Radiol 23:39–45CrossRefGoogle Scholar
  10. 10.
    Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 23:109–113CrossRefGoogle Scholar
  11. 11.
    Llovet JM, Di Biseglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:678–711Google Scholar
  12. 12.
    Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the barcelona 2000 EASL conference. J Hepatol 35:421–430CrossRefGoogle Scholar
  13. 13.
    Tateishi R, Shiina S, Teratami T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 103:1201–1209CrossRefGoogle Scholar
  14. 14.
    Tanabe KK, Curley SA, Dodd GD et al (2004) Radiofrequency ablation: the experts weigh in. Cancer 100:641CrossRefGoogle Scholar
  15. 15.
    Kagawa T, Koizumi J, Koijima S et al (2010) Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 116:3638–3644CrossRefGoogle Scholar
  16. 16.
    Rossi S, Garbagnati F, Lencioni R et al (2000) Percutaneous radiofrequency thermal ablation of non resectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217:119–126CrossRefGoogle Scholar
  17. 17.
    Ohmoto K, Yoshioku N, Tomiyama Y et al (2007) Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinoma: a retrospective comparative study. Hepatogastroenterology 54:985–989PubMedGoogle Scholar
  18. 18.
    Akahane M, Koga H, Kato N et al (2005) Complications of percutaneous radiofrequency ablation for hepatocellular carcinoma: imaging spectrum and management. Radiographics 25:S57–S68CrossRefGoogle Scholar
  19. 19.
    Sato M, Tateishi R, Yasunaga H et al (2012) Mortality and morbidity of hepatectomy, radiofrequency ablation and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 47:1125–1133CrossRefGoogle Scholar
  20. 20.
    Howenstein MJ, Sato KT (2010) Complication of radiofrequency ablation of hepatic, pulmonary and renal neoplasms. Semin Interv Radiol 27:285–295CrossRefGoogle Scholar
  21. 21.
    Frich L, Halvarsen PS, Skulstad H et al (2007) Microbubbles in the pulmonary artery generated during experimental hepatic radiofrequency ablation is correlated with increased pulmonary arterial pressure. J Vasc Interv Radiol 18:437–442CrossRefGoogle Scholar
  22. 22.
    Wah TZ, Arellano RS, Gervais DA et al (2005) Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology 237:1097–1102CrossRefGoogle Scholar
  23. 23.
    Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508CrossRefGoogle Scholar
  24. 24.
    Munireddy S, Katz S, Somasundar P et al (2012) Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol 3:69–77PubMedPubMedCentralGoogle Scholar
  25. 25.
    Govaert KM, van Kessel CS, Lolkema M et al (2012) Does radiofrequency ablation add to chemotherapy for unresectable liver metastasis? Curr Colorectal Cancer Rep 8:130–137CrossRefGoogle Scholar
  26. 26.
    Ruers T, Punt CJ, van Coevorden F et al (2010) Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRLM). J Clin Oncol 28(15 suppl):abstract 3526CrossRefGoogle Scholar
  27. 27.
    Weng M, Zhang Y, Zhou D et al (2012) Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One 7:e45493CrossRefGoogle Scholar
  28. 28.
    Donado M, Ribero D, Morris-Stiff G et al (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1:20–27Google Scholar
  29. 29.
    Shibata T, Yamamoto Y, Yamamoto N et al (2003) Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 14:1535–1542CrossRefGoogle Scholar
  30. 30.
    Sipperstein AE, Berber E, Ballem N et al (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10 year experience. Ann Surg 246:559–565CrossRefGoogle Scholar
  31. 31.
    Abdalla EK, Vauthey JN, Ellis JM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825CrossRefGoogle Scholar
  32. 32.
    Bleicher RJ, Allegra DP, Nora DT et al (2003) Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10:52–58CrossRefGoogle Scholar
  33. 33.
    Yangkui Gu, Zhimei Huang, Haifeng Gu, Fei Gao, Tianqi Zhang, Senmiao Huang, Jinhua Huang, (2018) Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation?. CardioVascular and Interventional Radiology 41 (6):912–919Google Scholar
  34. 34.
    Hellman P, Ladjevardi S, Kogseid B et al (2002) Radiofrequency tissue ablation using cooltip for liver metastases of endocrine tumors. World J Surg 26:1052–1056CrossRefGoogle Scholar
  35. 35.
    Berber E, Flesher N, Sipperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985–990CrossRefGoogle Scholar
  36. 36.
    Massaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-years experience evaluating predictors of survival. Surgery 142:10–19CrossRefGoogle Scholar
  37. 37.
    Gc H, Tunkali K, Tatli S et al (2008) Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 19:1311CrossRefGoogle Scholar
  38. 38.
    Dupuy DE, DiPetrillo T, Gandhi S et al (2006) Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest 129:738–745CrossRefGoogle Scholar
  39. 39.
    Pereira PL, Massala S (2012) Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol 35:247–254CrossRefGoogle Scholar
  40. 40.
    De Baere T (2011) Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol 34:241–251CrossRefGoogle Scholar
  41. 41.
    De Baere T, Palussiere J, Auperin A et al (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240:587–596CrossRefGoogle Scholar
  42. 42.
    Yoshimatsu R, Yamagami T, Terayama K et al (2009) Delayed and recurrent pneumothorax after radiofrequency ablation of lung tumors. Chest 135:1002–1009CrossRefGoogle Scholar
  43. 43.
    Sakurai J, Mimura H, Gobara H et al (2010) Pulmonary artery pseudoaneurysm related to radiofrequency ablation of lung tumor. Cardiovasc Intervent Radiol 33:413–416CrossRefGoogle Scholar
  44. 44.
    Pennathur A, Luketich JD, Abbas G et al (2007) Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 134:857–864CrossRefGoogle Scholar
  45. 45.
    Kodama H, Yamakado K, Takaki H et al (2012) Lung radiofrequency ablation for the treatment of unresectable recurrent non-small cell lung cancer after surgical intervention. Cardiovasc Intervent Radiol 35:563–569CrossRefGoogle Scholar
  46. 46.
    Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243:268–275CrossRefGoogle Scholar
  47. 47.
    Gillams A, Khan Z, Osborn P et al (2013) Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 36(3):724–730CrossRefGoogle Scholar
  48. 48.
    Davalos RV, Mir LM, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231CrossRefGoogle Scholar
  49. 49.
    Wendler JJ, Porch M, Hühne S et al (2013) Short and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Intervent Radiol 36(2):512–520CrossRefGoogle Scholar
  50. 50.
    Wendler JJ, Pech M, Blaschke S et al (2012) Angiography in the isolated perfused kidney: radiological evaluation of vascular protection in tissue ablation by irreversible electroporation. Cardiovasc Intervent Radiol 35:383–390CrossRefGoogle Scholar
  51. 51.
    Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921CrossRefGoogle Scholar
  52. 52.
    Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590CrossRefGoogle Scholar
  53. 53.
    Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786CrossRefGoogle Scholar
  54. 54.
    Nakajo M, Kobayashi H, Shimabukuro K et al (1988) Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 29:1066–1077PubMedGoogle Scholar
  55. 55.
    Kan Z, Sato M, Ivancev K et al (1993) Distribution and effect of iodized poppy seed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 186:261–266CrossRefGoogle Scholar
  56. 56.
    Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead Block for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541–551CrossRefGoogle Scholar
  57. 57.
    Nicolini A, Martinetti L, Crespi S et al (2010) Transarterial chemoembolization with epirubicineluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21(3):327–332CrossRefGoogle Scholar
  58. 58.
    Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342CrossRefGoogle Scholar
  59. 59.
    Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481CrossRefGoogle Scholar
  60. 60.
    Lee KH, Liapi EA, Cornell C et al (2010) Doxorubicin-loaded Quadrasphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 33(3):576–582CrossRefGoogle Scholar
  61. 61.
    Gupta S, Wright KC, Ensor J et al (2011) Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. Cardiovasc Intervent Radiol 34(5):1021–1030CrossRefGoogle Scholar
  62. 62.
    Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34(4):774–785CrossRefGoogle Scholar
  63. 63.
    Brown DB, Cardella JF, Sacks D et al (2006) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 17(2 Pt 1):225–232CrossRefGoogle Scholar
  64. 64.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRefGoogle Scholar
  65. 65.
    Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefGoogle Scholar
  66. 66.
    Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30(1):6–25CrossRefGoogle Scholar
  67. 67.
    Malagari K, Pomoni M, Moschouris H et al (2012) Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 35(5):1119–1128CrossRefGoogle Scholar
  68. 68.
    Burrel M, Reig M, Forner A et al (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 56(6):1330–1335CrossRefGoogle Scholar
  69. 69.
    Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterialinfusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenoustherapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395PubMedGoogle Scholar
  70. 70.
    Martin RC II, Scoggins CR, Tomalty D et al (2012) Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16(8):1531–1538CrossRefGoogle Scholar
  71. 71.
    Stuart K (2003) Chemoembolization in the management of liver tumors. Oncologist 8:425–437CrossRefGoogle Scholar
  72. 72.
    Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361CrossRefGoogle Scholar
  73. 73.
    Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5):776–783. (discussion 83–85)CrossRefGoogle Scholar
  74. 74.
    Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602CrossRefGoogle Scholar
  75. 75.
    Roche A, Girish BV, de Baère T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140PubMedGoogle Scholar
  76. 76.
    Stokes KR, Stuart K, Clouse ME (1993) Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 4(3):341–345CrossRefGoogle Scholar
  77. 77.
    Memon K, Lewandowski RJ, Mulcahy MF et al (2012) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894CrossRefGoogle Scholar
  78. 78.
    Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64CrossRefGoogle Scholar
  79. 79.
    Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425CrossRefGoogle Scholar
  80. 80.
    Kooby DA, Egnatashvili V, Srinivasan S et al (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolisation for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224–230CrossRefGoogle Scholar
  81. 81.
    Carr BI, Kondragunta V, Buch SC et al (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305–1314CrossRefGoogle Scholar
  82. 82.
    Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928CrossRefGoogle Scholar
  83. 83.
    Katsanos K, Sabharwal T, Adam A (2010) Stenting of the upper gastrointestinal tract: current status. Cardiovasc Intervent Radiol 33:690–705CrossRefGoogle Scholar
  84. 84.
    Adam A, Morgan R, Ellul J et al (1996) A new design of the esophageal wallstent endoprosthesis resistant to distal migration. Am J Roentgenol 170:1477–1482CrossRefGoogle Scholar
  85. 85.
    Sabharwal T, Hamady MJ, Chui S et al (2003) A randomized prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third esophageal carcinoma. Gut 52:922–926CrossRefGoogle Scholar
  86. 86.
    Sabharwal T, Morale JP, Irani FG et al (2005) Quality improvement guidelines for placement of esophageal stents. Cardiovasc Intervent Radiol 28:284–288CrossRefGoogle Scholar
  87. 87.
    Farrugia M, Morgan RA, Latham JA et al (1997) Perforation of the esophagus secondary to insertion of covered wallstent endoprostheses. Cardiovasc Intervent Radiol 20:428–430CrossRefGoogle Scholar
  88. 88.
    Katsanos K, Sabharwal T, Adam A (2011) Stenting of the lower gastrointestinal tract: current status. Cardiovasc Intervent Radiol 34:462–473CrossRefGoogle Scholar
  89. 89.
    Baerlocher MO, Asch MR, Dixon P et al (2008) Interdisciplinary Canadian guidelines on the use of metal stents in the gastrointestinal tract for oncological indications. Can Assoc Radiol J 59:107–122PubMedGoogle Scholar
  90. 90.
    Adam A, Watkinson A (1996) Interventional radiology-a practical guide. Radcliffe Medical Press, OxfordGoogle Scholar
  91. 91.
    Lammer J, Hausegger KA, Fluckiger F et al (1996) Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 201:167–172CrossRefGoogle Scholar
  92. 92.
    Kaskarelis IS, Papadaki MG, Papageorgiou GN et al (1999) Long-term follow-up in patients with malignant biliary obstruction after percutaneous placement of uncovered wallstent endoprosthesis. Acta Radiol 40:528–533CrossRefGoogle Scholar
  93. 93.
    Brountzos EN, Ptochis N, Panagiotou I et al (2006) A survival analysis of patients with malignant biliary strictures treated by percutaneous metallic stenting. Cardiovasc Intervent Radiol 30:66–73CrossRefGoogle Scholar
  94. 94.
    Krokidis M, Fanelli F, Orgera G et al (2011) Percutaneous palliation of pancreatic head cancer: comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol 34:352–361CrossRefGoogle Scholar
  95. 95.
    Uthappa MC, Kellett MJ (2004) Interventional radiology in malignant urinary tract obstruction. In: Adam A, Dondelinger R, Mueller PR (eds) Interventional radiology in cancer. Springer, BerlinGoogle Scholar
  96. 96.
    Dyer RB, Regan JD, Kavanagh PV et al (2002) Percutaneous nephrostomy with extension of the technique: step by step. Radiographics 22:503–525CrossRefGoogle Scholar
  97. 97.
    Silverman SG, Deuson TE, Kane N et al (1998) Percutaneous abdominal biopsy: cost-identification analysis. Radiology 206(2):429–435CrossRefGoogle Scholar
  98. 98.
    Smith EH (1991) Complications of percutaneous abdominal fine-needle biopsy. Radiology 178(1):253–258CrossRefGoogle Scholar
  99. 99.
    Cham MD, Lane ME, Henschke CI et al (2008) Lung biopsy: special techniques. Semin Respir Crit Care Med 29(4):335–349CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael K. Glynos
    • 1
  • Katerina S. Malagari
    • 2
  1. 1.Department of Interventional RadiologyHygeia HospitalMarousiGreece
  2. 2.Department of RadiologyUniversity of AthensAthensGreece

Personalised recommendations